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Inflammatory conditions in selected organs increase the risk of cancer. 
Compounds of the inflammatory tumor microenvironment include leukocytes, 
cytokines, complement components, and are orchestrated by transcription 
factors, such as STAT3 (Signal Transducer and Activator of Transcription 3) and NF-
kB. Two main approaches have been explored to inhibit STAT3 signalling: 
 - indirect, inhibiting the upstream tyrosine kinases that are responsible for STAT3 
activation or blocking factors such as JAK, Src, Bcr-Abl, FLT3 and EGFR that are 
involved in the activation of STAT3 signalling, inducing tumour-cell apoptosis but it 
is poor selective. 
- direct, by interaction of small molecules with the protein. In this selective 
approach the starting point is the crystallographic structure of STAT3-SH2 domain. 
Most of the synthesized thiosulfonate-hybrids are able to strongly 
and selectively bind STAT3-SH2 domain (Table 1), whereas the 
parent drugs were completely devoid of this ability (Table 2).  
Studies are ongoing to better define the profile of our new 
methanethiosulfonate derivatives as potential dual STAT3/NF-kB 
inhibitors. 
Introduction 
Fig.2: Schematic diagram of the multiplexed Alpha assay for STAT3 [3]. 
S-methylmethanethiosulfonate has been shown to inhibit colon tumor incidence 
when administered to rats during the post-initiation phase of carcinogenesis [1]. 
Recently, a new methanethiosulfonate derivative of valproic acid (ACS33) was 
reported by some of us to show good in vitro antiproliferative activity and to 
inhibit in vivo the growth of PC3 in subcutaneous xenograft mice models [2].  
Fig.1: Structure of the studied thiosulfonate hybrids.  
 
Since the influence of methanethiosulfonates on STAT3 activity has not been 
yet studied, we decided to synthesize a set of thiosulfonate-drug hybrids 
(Fig.1) and to submit them and their parent compounds to the AlphaScreen-
based assay, to investigate their ability to inhibit the binding of STAT3-SH2 
domain to its phosphopeptidic ligand [3] Moreover, in order to check the 
selectivity of our molecules, we also decided to test their ability to bind SH2 
domain of STAT1, which exhibits a high degree of sequence homology to 
STAT3. 
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Table 2: In vitro AlphaScreen assay results for parent compounds, expressed as inhibition % . 
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AlphaScreen technology is capable of analyzing protein-protein or protein-
peptide interactions and it is an useful method to detect the interactions 
between the SH2 domain and the pTyr-containing peptide. This test is bead-
based non-radioactive assay system for detecting biomolecular interactions in a 
microlitre plate format. In details sandwich antibody complexes are captured by 
AlphaScreen donor and acceptor beads (Fig.2), bringing them into close 
proximity: the excitation of the donor bead provokes the relase of a singlet 
oxygen molecules that triggers a cascade of energy transfer in the acceptor 
bead, resulting in a fluorescent signal between 520 and 620 nm.  
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Valproic Acid 
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Diclofenac sodium salt 
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Ferulic Acid 
 
0.2 ± 8.2 
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Table 1: In vitro AlphaScreen assay results for the new synthesized compounds. 
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